Stephanie Proulx

Prof. Stephanie Proulx

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2015 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Closed access
PDF file
OROlivier Roy
Olivier Roy
VLVéronique Beaulieu Leclerc
Véronique Beaulieu Leclerc
JBJean-Michel Bourget
Jean-Michel Bourget
MTMathieu Thériault
Mathieu Thériault
Stephanie ProulxStephanie Proulx
Stephanie Proulx
Corneal endothelial cells often adopt a fibroblastic-like morphology in culture, a process that has been attributed to epithelial- or endothelial-to-mesenchymal transition (EMT or EndMT). Although being extensively studied in other cell types, this transition is less well characterized in the corneal endothelium. Because of their neuroectodermal origin and their in vivo mitotic arrest, corneal endothelial cells represent a particular tissue that deserves more attention. This review article presents the basic principles underlying EMT/EndMT, with emphasis on the current knowledge regarding the corneal endothelium. Furthermore, this review discusses cell culture conditions and major cell signaling pathways that have been identified as EndMT-triggering factors. Finally, it summarizes strategies that have been developed to inhibit EndMT in corneal endothelial cell culture. The review of current studies on corneal and classical EndMT highlights some research avenues to pursue in the future and underscores the need to extend our knowledge of this process in order to optimize usage of these cells in regenerative medicine.

1 July 2017 in Progress in Retinal and Eye Research
Verified
Journal Article
Closed access
IBIsabelle Brunette
Isabelle Brunette
CRCynthia J. Roberts
Cynthia J. Roberts
FVFrançois Vidal
François Vidal
MHMona Harissi-Dagher
Mona Harissi-Dagher
JLJean Lachaine
Jean Lachaine
MGMay Griffith
May Griffith

1 April 2011 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Closed access
PDF file
HLHubert Landry
Hubert Landry
AAAnahid Aminian
Anahid Aminian
LHLouis Hoffart
Louis Hoffart
ONOssama Nada
Ossama Nada
TBThouria Bensaoula
Thouria Bensaoula
IBIsabelle Brunette
Isabelle Brunette
Purpose. The authors conducted in vivo assessment of corneal endothelial toxicity of air and SF6 in the feline model. This research was motivated by the increased use of air in anterior segment surgery in human subjects. Methods. This was a prospective masked study. The eyes of 16 healthy adult cats were randomly assigned for the injection of 0.7 mL air into the anterior chamber of one eye and SF6 in the contralateral eye. Daily examination included slit lamp photographs, pachymetry, and tonometry. Specular microscopy was performed before, 7 days after, and 10 days after injection. The animals were euthanatized, and the corneas were processed for alizarin red-trypan blue staining and for light and electron microscopy. Results. SF6 remained in the anterior chamber significantly longer than air. Both groups showed postinjection inflammation, which on average was maximal at day 2 and more severe with SF6. No difference in IOP was observed between the two groups. Specular microscopy showed significant endothelial cell loss in the SF6 group (mean postinjection cell loss, 132 ± 50 cells/mm2) but not in the group injected with air. Alizarin red staining revealed significant regional differences in cell density only in the SF6 group and more pronounced endothelial cell loss in the superior area. Conclusions. These results indicate that both air and SF6 injected into the anterior chamber of the eye can induce intraocular reaction in the feline model and that SF6 is more toxic than air in terms of endothelial cell loss and anterior chamber inflammation.

1 February 2012 in Experimental Eye Research
Verified
Journal Article
Closed access
Stephanie ProulxStephanie Proulx
Stephanie Proulx
IBIsabelle Brunette
Isabelle Brunette

1 July 2009 in Tissue Engineering Part A
Verified
Journal Article
Closed access
Stephanie ProulxStephanie Proulx
Stephanie Proulx
CACaroline Audet
Caroline Audet
JUJeanne D'ARc Uwamaliya
Jeanne D'ARc Uwamaliya
ADAlexandre Deschambeault
Alexandre Deschambeault
PCPatrick Carrier
Patrick Carrier
Lucie GermainLucie Germain
Lucie Germain
The difficulties in obtaining good quality tissue for the replacement of corneas of patients suffering from endothelial dysfunctions have prompted us to evaluate the feasibility of producing a tissue-engineered (TE) corneal endothelium using devitalized human stromal carriers. Thus, corneal substitutes were produced by seeding cultured feline corneal endothelial cells on top of previously frozen human corneal stromas. After two weeks of culture to allow attachment and spreading of the seeded cells, the TE corneal endothelium was stained with alizarin red for endothelial cell count and fixed for histology, immunofluorescence labeling, scanning and transmission electron microscopy. Histology and Hoechst staining showed that there were no remaining cells in the devitalized stroma. After seeding, histology and transmission electron microscopy showed that the TE corneal endothelium formed a monolayer of tightly packed cells that were well adhered to Descemet's membrane. Scanning electron microscopy corroborated that the cells covered the entire posterior corneal surface and had an endothelial morphology. Alizarin staining showed that mean cell counts were 2272 ± 344 cells/mm2, indicating that the cell density was appropriate for grafting. The TE feline corneal endothelium also expressed the function-related proteins Na+/HCO3−, ZO-1, and Na+/K+-ATPase α1, and could easily be marked with a fluorescent tracker. This study demonstrates the feasibility of reconstructing a highly cellular and healthy corneal endothelium on devitalized human corneal stromas.

1 April 2018 in Tissue Engineering Part A
Verified
Journal Article
Open access
BGBenjamin Goyer
Benjamin Goyer
MTMathieu Thériault
Mathieu Thériault
SGSébastien P. Gendron
Sébastien P. Gendron
IBIsabelle Brunette
Isabelle Brunette
PRPatrick J Rochette
Patrick J Rochette
Stephanie ProulxStephanie Proulx
Stephanie Proulx
Primary corneal endothelial cell (CEC) cultures and 3D-engineered tissue models were used to study the aberrant deposition of extracellular matrix (ECM) in a vision impairing pathology known as Fuchs endothelial corneal dystrophy (FECD). CECs were isolated from excised Descemet membranes of patients with end-stage FECD. CECs isolated from healthy corneas served as controls. Microarray gene profiling was performed on postconfluent cultures of healthy and FECD cells. Protein expression analyses were conducted on tissue models that were engineered by seeding an endothelium on previously devitalized human stromal carriers. The engineered endothelia were kept in culture for 1–3 weeks to reform the endothelial monolayer. Protein expression of integrin subunits α4, α6, αv, and β1, as well as laminin, type IV collagen, fibronectin, clusterin, and transforming growth factor β-induced protein (TGFβIp) was then assessed by immunofluorescence. Microarray analysis showed nonstatistical twofold downregulation of collagen-coding genes (COL4A4, COL8A2, and COL21A1) and a twofold upregulation of the COL6A1, laminin α3 gene LAMA3, and integrin subunit α10 gene ITGA10 in FECD cells. Fibronectin type III domain containing 4 (FNDC4) and integrin β5 (ITGB5) genes was significantly upregulated in FECD cells. Immunostainings demonstrated that the protein expression of the integrin subunits α4, α6, αv, and β1, type IV collagen, as well as laminin remained similar between native and engineered endothelia. TGFβIp expression was found on the stromal side of both FECD and healthy Descemet's membrane, and only one out of three FECD specimens was positive for the clusterin protein. Interestingly, the ECM protein fibronectin was also found to have a stronger presence on engineered FECD tissues, a result consistent with the native FECD specimens. To conclude, this study allowed to identify fibronectin deposition as one of the first steps in the pathogenesis of FECD, as defined by our engineered tissue model. This opens the way to an entirely new perspective for in vitro pharmacological testing of new therapies for FECD, the leading indication for corneal transplantation in North America.